What is Embecta Corp.'s market cap?

Embecta Corp. (EMBC) has a market capitalization of $203.8M and trades on NASDAQ.

What is Embecta Corp.'s revenue and profitability?

Embecta Corp. generated $1.0B in trailing twelve-month revenue with net income of $111.9M, representing a net margin of 10.7%. Gross margin stands at 61.9%, with free cash flow of $204.7M. These figures are based on the Q1 2026 filing.

Who are Embecta Corp.'s competitors?

Embecta Corp.'s key competitors include Tandem Diabetes Care, Insulet Corporation, Medtronic, and others. These companies compete in similar markets and product categories.

Who does Embecta Corp. partner with?

Embecta Corp.'s notable partners include Becton, Dickinson and Company.

Where is Embecta Corp. headquartered?

Embecta Corp. is headquartered in United States of America and employs approximately 2,200 people. It has been publicly traded since 2022.

Embecta Corp.

EMBC

Embecta is a leading global medical device company dedicated to improving the lives of people living with diabetes through advanced injection technologies.

Market cap

$203.79M-66.6%

Revenue$1.0B-3.4%

Net income$111.9M+112%

Free cash flow$204.7M+416%

EPS (diluted)$1.89+112%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

May 5, 2026

Revenue$221.8MMiss by $13.9M EPS$0.27Miss by $0.15

Read the full report

Next report

Aug 7, 2026 (In 1 week)

Revenue estimate$254.5M

EPS estimate$0.26

Financials

Q2 2026

Income statement

See full

Revenue$221.8M-14.4%

Gross profit$127.8M-22.1%

Operating income$35.0M-44.4%

Net income-$4.1M-117%

EPS (diluted)-$0.07-118%

Balance sheet

See full

Cash & equivalents$193.4M-8.9%

Total debt$1.4B-12.5%

Total equity-$626.1M+15.0%

Total assets$1.0B-8.1%

Cash flow

See full

Operating cash flow$31.1M-2.2%

CapEx$500.0K+400%

Free cash flow$30.6M-3.5%

Valuation & ratios

Valuation

See full

Market cap$203.79M-66.6%

Enterprise value$1.38B-28.9%

P/E1.8×-6.1×

P/S0.2×-0.4×

Profitability

See full

Gross margin61.9%-1.6pp

Operating margin25.8%+9.7pp

Net margin10.7%+5.8pp

FCF margin19.6%+16.0pp

Returns & leverage

See full

Current ratio2.5×0.0×

Segments

By product

See full

Pen Needles$154.7M-17.8%

Safety$34.3M+0.3%

Syringes$26.3M-8.7%

Contract Manufacturing$2.5M-43.2%

Competitors

By market cap

Medtronic$107.81B-8.5%

Insulet$11.4B-44.4%

Tandem Diabetes Care$1.2B+4.9%

Beta Bionics, Inc.$712.5M+17.5%

Embecta Corp.$203.8M-69.2%

KORU Medical Systems$187.4M+19.1%

Retractable Technologies$20.1M-7.4%

Modular Medical$12.5M-67.1%

By revenue growth

Beta Bionics, Inc.+57.9%

Insulet+31.9%

KORU Medical Systems+23.3%

Medtronic+8.4%

Tandem Diabetes Care+4.5%

Embecta Corp.-3.4%

By net margin

Medtronic13.2%-0.7pp

Embecta Corp.10.73%+5.8pp

Insulet10.44%-7.9pp

KORU Medical Systems-5.27%+9.8pp

Tandem Diabetes Care-9.2%+9.5pp

Beta Bionics, Inc.-60.27%+41.4pp

Profile

Embecta is a leading global medical device company dedicated to improving the lives of people living with diabetes through advanced injection technologies. The company provides a comprehensive portfolio of insulin delivery solutions, including pen needles and syringes, used by millions of patients worldwide. Leveraging a century-long heritage, the company focuses on enhancing patient comfort, safety, and ease of use in daily diabetes management.

Competitive position

A global leader in diabetes injection devices with a 100-year heritage and products used by over 30 million people.

GeographiesUnited States, China, Ireland, Global

Customer segmentsPatients, Healthcare Providers, Retailers

Business modelManufacturing, Direct-to-Consumer, B2B

SuppliersCannula suppliers, Plastic resin suppliers, Adhesive and lubricant manufacturers, Rubber stopper suppliers, Packaging material providers

CustomersRetail pharmacies, Hospitals, Institutional healthcare channels, End-user patients with diabetes

CountryUnited States of America

Listed2022

Employees2.2K

CEODevdatt Kurdikar

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteembecta.com

FilingsSEC EDGAR

Ask your AI about Embecta Corp..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Embecta Corp.'s market cap?: Embecta Corp. (EMBC) has a market capitalization of $203.8M and trades on NASDAQ.
What is Embecta Corp.'s revenue and profitability?: Embecta Corp. generated $1.0B in trailing twelve-month revenue with net income of $111.9M, representing a net margin of 10.7%. Gross margin stands at 61.9%, with free cash flow of $204.7M. These figures are based on the Q1 2026 filing.
Who are Embecta Corp.'s competitors?: Embecta Corp.'s key competitors include Tandem Diabetes Care, Insulet Corporation, Medtronic, and others. These companies compete in similar markets and product categories.
Who does Embecta Corp. partner with?: Embecta Corp.'s notable partners include Becton, Dickinson and Company.
Where is Embecta Corp. headquartered?: Embecta Corp. is headquartered in United States of America and employs approximately 2,200 people. It has been publicly traded since 2022.